Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

Articles published in
J Neurol Neurosurg Psychiatry
    September 2022
  1. WILLUMSEN JS, Grytten N, Aarseth J, Myklebust TA, et al
    Mortality and cause of death in multiple sclerosis in western Norway 1950-2021: a registry-based linkage study.
    J Neurol Neurosurg Psychiatry. 2022 Sep 12. pii: jnnp-2022-329169.
    >> Share

    August 2022
  2. MARRIE RA, Fisk JD, Walld R, Bolton JM, et al
    Prescription opioid use in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Aug 26. pii: jnnp-2022-329508.
    >> Share

  3. CHO EB, Yeo Y, Jung JH, Jeong SM, et al
    Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea.
    J Neurol Neurosurg Psychiatry. 2022 Aug 26. pii: jnnp-2022-329628.
    >> Share

  4. BOSE G, Healy BC, Barro C, Glanz BI, et al
    Younger age at multiple sclerosis onset is associated with worse outcomes at age 50.
    J Neurol Neurosurg Psychiatry. 2022 Aug 11. pii: jnnp-2022-329353.
    >> Share

  5. KVISTAD SAS, Burman J, Lehmann AK, Tolf A, et al
    Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
    J Neurol Neurosurg Psychiatry. 2022;93:844-848.
    >> Share

    July 2022
  6. CHEN J, Diouf I, Taylor BV, Kalincik T, et al
    Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329223.
    >> Share

  7. KWON S, Jung SY, Han KD, Jung JH, et al
    Risk of Parkinson's disease in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea.
    J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329389.
    >> Share

  8. LASLETT LL, Honan C, Turner JA, Dagnew B, et al
    Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life.
    J Neurol Neurosurg Psychiatry. 2022 Jul 27. pii: jnnp-2022-329227.
    >> Share

  9. ROD BE, Torkildsen O, Myhr KM, Bo L, et al
    Safety of breast feeding during rituximab treatment in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jul 25. pii: jnnp-2022-329545.
    >> Share

  10. MEYER-ARNDT L, Braun J, Fauchere F, Vanshylla K, et al
    SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
    J Neurol Neurosurg Psychiatry. 2022 Jul 14. pii: jnnp-2022-329395.
    >> Share

    June 2022
  11. ABDELHAK A, Cordano C, Boscardin WJ, Caverzasi E, et al
    Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jun 16. pii: jnnp-2022-329221.
    >> Share

  12. WANDALL-HOLM MF, Buron MD, Kopp TI, Thielen K, et al
    Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jun 10. pii: jnnp-2022-329058.
    >> Share

  13. ETEMADIFAR M, Nouri H, Pitzalis M, Idda ML, et al
    Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2022 Jun 10. pii: jnnp-2022-329123.
    >> Share

  14. LIE IA, Kacar S, Wesnes K, Brouwer I, et al
    Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study.
    J Neurol Neurosurg Psychiatry. 2022 Jun 1. pii: jnnp-2021-328568.
    >> Share

    May 2022
  15. MARGONI M, Pagani E, Meani A, Storelli L, et al
    Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study.
    J Neurol Neurosurg Psychiatry. 2022 May 17. pii: jnnp-2022-328908.
    >> Share

  16. SIMPSON-YAP S, Atvars R, Blizzard L, van der Mei I, et al
    Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia.
    J Neurol Neurosurg Psychiatry. 2022 May 16. pii: jnnp-2022-328932.
    >> Share

    April 2022
  17. COMABELLA M, Sastre-Garriga J, Carbonell-Mirabent P, Fissolo N, et al
    Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Apr 29. pii: jnnp-2022-329020.
    >> Share

  18. PROSPERINI L, Lucchini M, Ruggieri S, Tortorella C, et al
    Shift of multiple sclerosis onset towards older age.
    J Neurol Neurosurg Psychiatry. 2022 Apr 27. pii: jnnp-2022-329049.
    >> Share

  19. SUGIYAMA A, Kuwabara S
    Microstructural changes in the normal appearance cerebral cortex of multiple sclerosis detected by an advanced diffusion MRI technique.
    J Neurol Neurosurg Psychiatry. 2022 Apr 25. pii: jnnp-2021-328089.
    >> Share

  20. BRENTON JN, Lehner-Gulotta D, Woolbright E, Banwell B, et al
    Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits.
    J Neurol Neurosurg Psychiatry. 2022 Apr 13. pii: jnnp-2022-329074.
    >> Share

  21. MAGYARI M, Koch-Henriksen N
    Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Apr 7. pii: jnnp-2022-328994.
    >> Share

  22. EID K, Torkildsen O, Aarseth J, Aalstad M, et al
    Association of adverse childhood experiences with the development of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Apr 4. pii: jnnp-2021-328700.
    >> Share

    March 2022
  23. WILLIAMS T, Mishra R, Bharkhada B, Shields A, et al
    Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study.
    J Neurol Neurosurg Psychiatry. 2022 Mar 10. pii: jnnp-2021-328340.
    >> Share

    February 2022
  24. RAUBER S, Korsen M, Huntemann N, Rolfes L, et al
    Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
    J Neurol Neurosurg Psychiatry. 2022 Feb 22. pii: jnnp-2021-328197.
    >> Share

    January 2022
  25. MASUDA H, Mori M, Hirano S, Uzawa A, et al
    Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    J Neurol Neurosurg Psychiatry. 2022;93:32-40.
    >> Share

    November 2021
  26. PREZIOSA P, Pagani E, Bonacchi R, Cacciaguerra L, et al
    In vivo detection of damage in multiple sclerosis cortex and cortical lesions using NODDI.
    J Neurol Neurosurg Psychiatry. 2021 Nov 19. pii: jnnp-2021-327803.
    >> Share

  27. NIJ BIJVANK J, Uitdehaag BMJ, Petzold A
    Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics.
    J Neurol Neurosurg Psychiatry. 2021 Nov 11. pii: jnnp-2021-327468.
    >> Share

    October 2021
  28. KONIG M, Lorentzen AR, Torgauten HM, Tran TT, et al
    Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
    J Neurol Neurosurg Psychiatry. 2021 Oct 20. pii: jnnp-2021-327612.
    >> Share

  29. MASUDA H, Mori M, Kuwabara S
    Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Oct 19. pii: jnnp-2021-326821.
    >> Share

  30. SIMPSON-YAP S
    Relationships with MS not unique to relapsing-onset phenotypes.
    J Neurol Neurosurg Psychiatry. 2021;92:1029-1030.
    >> Share

    September 2021
  31. TAYLOR BV
    Sequencing of and escalation paradigms for MS therapies: time for a rethink?
    J Neurol Neurosurg Psychiatry. 2021;92:913.
    >> Share

    August 2021
  32. DI FILIPPO M, Cordioli C, Malucchi S, Annovazzi P, et al
    mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Aug 18. pii: jnnp-2021-327200.
    >> Share

  33. MONSCHEIN T, Hartung HP, Zrzavy T, Barnett M, et al
    Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.
    J Neurol Neurosurg Psychiatry. 2021 Aug 5. pii: jnnp-2021-326839.
    >> Share

  34. LOUAPRE C, Ibrahim M, Maillart E, Abdi B, et al
    Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
    J Neurol Neurosurg Psychiatry. 2021 Aug 2. pii: jnnp-2021-326904.
    >> Share

    July 2021
  35. MARGONI M, Villani U, Finos L, Franciotta S, et al
    Neurite orientation dispersion and density imaging discloses early changes in the normal-appearing white matter in paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jul 16. pii: jnnp-2021-326355.
    >> Share

  36. DUAN Y, Zhuo Z, Li H, Tian DC, et al
    Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
    J Neurol Neurosurg Psychiatry. 2021;92:709-716.
    >> Share

    June 2021
  37. WANG C, Barton J, Kyle K, Ly L, et al
    Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.
    J Neurol Neurosurg Psychiatry. 2021 Jun 29. pii: jnnp-2021-326164.
    >> Share

    May 2021
  38. HEDSTROM AK, Hillert J, Olsson T, Alfredsson L, et al
    Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 May 13. pii: jnnp-2020-325688.
    >> Share

    April 2021
  39. COLATO E, Stutters J, Tur C, Narayanan S, et al
    Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes.
    J Neurol Neurosurg Psychiatry. 2021 Apr 20. pii: jnnp-2020-325610.
    >> Share

    March 2021
  40. HAIDER L, Chung K, Birch G, Eshaghi A, et al
    Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up.
    J Neurol Neurosurg Psychiatry. 2021 Mar 30. pii: jnnp-2020-325421.
    >> Share

  41. PFEUFFER S, Ruck T, Pul R, Rolfes L, et al
    Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
    J Neurol Neurosurg Psychiatry. 2021 Mar 12. pii: jnnp-2020-325304.
    >> Share

  42. HEDSTROM AK, Hillert J, Brenner N, Butt J, et al
    DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325676.
    >> Share

  43. MURPHY OC, Mukharesh L, Salazar-Camelo A, Pardo CA, et al
    Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325274.
    >> Share

    February 2021
  44. KOCH-HENRIKSEN N
    It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease.
    J Neurol Neurosurg Psychiatry. 2021 Feb 9. pii: jnnp-2020-325684.
    >> Share

    January 2021
  45. BURON MD, Kalincik T, Sellebjerg F, Sorensen PS, et al
    Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324869.
    >> Share

  46. PREZIOSA P, Bouman PM, Kiljan S, Steenwijk MD, et al
    Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324391.
    >> Share

    November 2020
  47. WIJBURG MT, Warnke C, McGuigan C, Koralnik IJ, et al
    Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications.
    J Neurol Neurosurg Psychiatry. 2020 Nov 23. pii: jnnp-2020-324534.
    >> Share

  48. CUNNIFFE N, Vuong KA, Ainslie D, Baker D, et al
    Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Nov 12. pii: jnnp-2020-324286.
    >> Share

  49. KEIR LHM, Breen DP
    REM sleep behaviour disorder in patients without synucleinopathy.
    J Neurol Neurosurg Psychiatry. 2020;91:1239-1240.
    >> Share

    October 2020
  50. ZHUKOVSKY C, Sandgren S, Silfverberg T, Einarsdottir S, et al
    Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
    J Neurol Neurosurg Psychiatry. 2020 Oct 26. pii: jnnp-2020-323992.
    >> Share

  51. ANNUNZIATA P
    More time, more safety: is this the future optimal way for natalizumab treatment in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2020 Oct 21. pii: jnnp-2020-324032.
    >> Share

  52. CHISARI CG, Grimaldi LM, Salemi G, Ragonese P, et al
    Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Oct 14. pii: jnnp-2020-323472.
    >> Share

    August 2020
  53. EVANGELOU N, Garjani A, dasNair R, Hunter R, et al
    Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register.
    J Neurol Neurosurg Psychiatry. 2020 Aug 27. pii: jnnp-2020-324449.
    >> Share

    July 2020
  54. COMPSTON A
    Review: Multiple sclerosis in the digital age: 'seeing through a glass darkly'.
    J Neurol Neurosurg Psychiatry. 2020 Jul 24. pii: jnnp-2020-323235.
    >> Share

  55. CHISARI CG, Solaro C, Annunziata P, Bergamaschi R, et al
    Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
    J Neurol Neurosurg Psychiatry. 2020 Jul 13. pii: jnnp-2019-322480.
    >> Share

    June 2020
  56. BUTZKUEVEN H, Kappos L, Wiendl H, Trojano M, et al
    Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
    J Neurol Neurosurg Psychiatry. 2020;91:660-668.
    >> Share

    May 2020
  57. ABRAHAMYAN S, Eberspacher B, Hoshi MM, Aly L, et al
    Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 May 5. pii: jnnp-2020-322941.
    >> Share

  58. PREZIOSA P, Rocca MA, Pagani E, Storelli L, et al
    Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    J Neurol Neurosurg Psychiatry. 2020;91:493-502.
    >> Share

    April 2020
  59. CHATAWAY J
    Distribution of plaques in the cerebrum in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Apr 20. pii: jnnp-2019-322431.
    >> Share

    March 2020
  60. ARNOLD DL, Banwell B, Bar-Or A, Ghezzi A, et al
    Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study.
    J Neurol Neurosurg Psychiatry. 2020 Mar 4. pii: jnnp-2019-322138.
    >> Share

  61. ESHAGHI A
    First approved treatment in children with multiple sclerosis slows brain atrophy.
    J Neurol Neurosurg Psychiatry. 2020 Mar 4. pii: jnnp-2019-322519.
    >> Share

    February 2020
  62. GERALDES R, Jurynczyk M, Dos Passos G, Prichler A, et al
    Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Feb 7. pii: jnnp-2019-322369.
    >> Share

  63. LIU J, Mori M, Sugimoto K, Uzawa A, et al
    Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS.
    J Neurol Neurosurg Psychiatry. 2020;91:132-139.
    >> Share

    January 2020
  64. PROSPERINI L, Mancinelli C, Haggiag S, Cordioli C, et al
    Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Jan 23. pii: jnnp-2019-322348.
    >> Share

  65. SIMPSON S JR
    Keeping people with MS in the workforce through effective treatment.
    J Neurol Neurosurg Psychiatry. 2020;91:6.
    >> Share

  66. ROMAN S
    Using clinically stable disease (NEDA 2) as a proxy for disease impact and employment in MS paints an incomplete picture.
    J Neurol Neurosurg Psychiatry. 2020;91:5.
    >> Share

    November 2019
  67. CHALMER TA, Buron M, Illes Z, Papp V, et al
    Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Nov 14. pii: jnnp-2019-321523.
    >> Share

    May 2019
  68. TALLANTYRE EC, Major PC, Atherton MJ, Davies WA, et al
    How common is truly benign MS in a UK population?
    J Neurol Neurosurg Psychiatry. 2019;90:522-528.
    >> Share

    March 2019
  69. GIOVANNONI G
    The unintended consequences of NICE.
    J Neurol Neurosurg Psychiatry. 2019;90:247-248.
    >> Share

  70. SCARPAZZA C, Signori A, Prosperini L, Sormani MP, et al
    Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.
    J Neurol Neurosurg Psychiatry. 2019;90:261-267.
    >> Share

    January 2019
  71. SORMANI MP, De Stefano N, Giovannoni G, Langdon D, et al
    Learning ability correlates with brain atrophy and disability progression in RRMS.
    J Neurol Neurosurg Psychiatry. 2019;90:38-43.
    >> Share

  72. WIJBURG MT, Warnke C, Barkhof F, Uitdehaag BMJ, et al
    Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
    J Neurol Neurosurg Psychiatry. 2019;90:44-46.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016